1. Home
  2. TMDX vs IBRX Comparison

TMDX vs IBRX Comparison

Compare TMDX & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TMDX
  • IBRX
  • Stock Information
  • Founded
  • TMDX 1998
  • IBRX 2014
  • Country
  • TMDX United States
  • IBRX United States
  • Employees
  • TMDX N/A
  • IBRX N/A
  • Industry
  • TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TMDX Health Care
  • IBRX Health Care
  • Exchange
  • TMDX Nasdaq
  • IBRX Nasdaq
  • Market Cap
  • TMDX 2.3B
  • IBRX 2.4B
  • IPO Year
  • TMDX 2019
  • IBRX N/A
  • Fundamental
  • Price
  • TMDX $88.24
  • IBRX $2.47
  • Analyst Decision
  • TMDX Buy
  • IBRX Strong Buy
  • Analyst Count
  • TMDX 10
  • IBRX 5
  • Target Price
  • TMDX $118.44
  • IBRX $11.35
  • AVG Volume (30 Days)
  • TMDX 1.1M
  • IBRX 8.0M
  • Earning Date
  • TMDX 04-29-2025
  • IBRX 05-08-2025
  • Dividend Yield
  • TMDX N/A
  • IBRX N/A
  • EPS Growth
  • TMDX N/A
  • IBRX N/A
  • EPS
  • TMDX 1.01
  • IBRX N/A
  • Revenue
  • TMDX $441,540,000.00
  • IBRX $14,745,000.00
  • Revenue This Year
  • TMDX $25.33
  • IBRX $621.53
  • Revenue Next Year
  • TMDX $20.53
  • IBRX $163.57
  • P/E Ratio
  • TMDX $87.37
  • IBRX N/A
  • Revenue Growth
  • TMDX 82.74
  • IBRX 2270.58
  • 52 Week Low
  • TMDX $55.00
  • IBRX $2.28
  • 52 Week High
  • TMDX $177.37
  • IBRX $10.53
  • Technical
  • Relative Strength Index (RSI)
  • TMDX 70.61
  • IBRX 41.67
  • Support Level
  • TMDX $82.62
  • IBRX $2.35
  • Resistance Level
  • TMDX $88.48
  • IBRX $3.04
  • Average True Range (ATR)
  • TMDX 5.48
  • IBRX 0.28
  • MACD
  • TMDX 1.98
  • IBRX -0.02
  • Stochastic Oscillator
  • TMDX 99.09
  • IBRX 13.19

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: